Search Results

XOMA Corporation entered into a merger agreement to acquire Kinnate Biopharma Inc. for a base cash price per share of Kinnate common stock of $2.3352 per share and an additional cash amount of not more than $0.2527 per share.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties.

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

As the biopharma industry grapples with the uncertain macro environment brought on by the new administration, CEOs, regulators and many others speak out.

Kinnate Biopharma Inc. announced it has entered into a definitive merger agreement whereby XOMA Corporation will acquire Kinnate for a price per share of Kinnate common stock of between $2.3352 and $2.5879 in cash, consisting of a base cash price of $2.3352 per share and an additional cash amount of up to $0.2527 per share.

During the first quarter, 22 rounds of biopharma layoffs in California affected about 995 employees total, while 17 rounds in Massachusetts impacted around 410 people, based on BioSpace estimates. Meanwhile, competition for jobs in those states increased year over year, according to BioSpace data.

Health and Human Services employees aren’t the only ones out of work. Thousands of private-sector biopharma professionals lost their jobs in the first quarter.

Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced financial results for the third quarter of 2023 and recent corporate updates.

XOMA Corporation announced it has entered an agreement to acquire Kinnate Biopharma Inc. for a base cash price of $2.3352 per share and an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a non-transferable contingent value right.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or “the Company”), a clinical-stage precision oncology company, today announced pipeline updates and a reprioritization plan, as well as a workforce restructuring, based on a strategic review of its business.